MediPharm Labs has announced a senior leadership transition.
To prepare the Company for its next phase of growth and to drive cost savings and efficiency improvements, MediPharm Labs have made the following changes in its senior leadership structure as well as roles and responsibilities:
- Pat McCutcheon will step down as Chief Executive Officer but retain his role as Chairman of the Board
- Keith Strachan will assume the role of Interim Chief Executive Officer
- Warren Everitt will continue as Chief Executive Officer, Asia Pacific
- Olga Utkutug appointed Interim Chief Financial Officer effective December 8, 2020
- The Company will also immediately begin a process to search for a permanent Chief Executive Officer. A search for a new Chief Financial Officer is already underway.
“The time has come to move beyond our start-up structure and put in place the best people to execute our strategy and guide the way to better financial performance including our return to profitability,” said Mr. McCutcheon. “Keith and Warren have been instrumental to the growth of MediPharm. They will continue to be aligned on executing our large pipeline of domestic and international growth contracts in hand as well as new opportunities in Canada, Europe and Asia Pacific. We are in a tremendous position to realize global market share with our two GMP platforms. As Chairman, I look forward to working with the Board in the search for our new CFO and a permanent CEO while supporting Keith and Warren and driving forward our strategic growth initiatives.”
“MediPharm Labs has a strong foundation, excellent customer relationships, differentiated capabilities and a great future,” said Keith Strachan. “We have a clear mandate from the Board to step up the pace of our growth while keeping a tight grip on expenses to create shareholder value.”
For more information:
MediPharm Labs
151 John Street, Barrie
+1 705 719 7425
medipharmlabs.com